The European Union (EU) is able to assist the German firm BioNTech to extend the manufacturing of the vaccine in opposition to covid-19, earlier than the bottleneck which are occurring because of the international scarcity of manufacturing capability, in keeping with European Well being Commissioner Stella Kyriakides.
“We perceive that everybody is trying on the price of vaccination. The bottleneck proper now is just not the quantity of orders, however the lack of world manufacturing capability. That is additionally true for BioNTech “, stated the commissioner in an interview with the German company DPA launched by its press service.
The vaccine developed by BioNTech with the American Pfizer is up to now the one one approved within the EU and international locations are presently going through shortages to immunize the complete inhabitants, whereas criticism grows in a few of them for the slowness of vaccination, notably in Germany.
On this scenario, BioNTech introduced this Saturday that it’s going to enhance its manufacturing capability and attributed the present scarcity partly to EU buying coverage through which the method has been slower than in different components of the world.
The commissioner defended this Sunday the technique adopted by Brussels to take a position from the start in varied vaccines in improvement to make sure that international locations had entry to at least one that was efficient.
“The scenario will enhance step-by-step. We have now been negotiating for additional doses of BioNTech vaccine a very long time and we’re prepared once more to assist broaden manufacturing capability, “he stated within the interview.
The European Fee, which offered 100 million euros in financing to BioNTech for the event of the vaccine, it obtained 200 million doses of it in December and has exercised an possibility to amass 100 million extra doses.
Kyriakides recalled that different producers with whom the EU has contracts are about to see their vaccinations accredited and that, if all candidates are accredited, Europe may have greater than 2 billion doses out there. The doses achieved by Brussels are then distributed proportionally among the many international locations.
Along with the Pfizer / BioNTech vaccine, the European Medicines Company plans to approve the American one this month Fashionable, whereas the one developed by AstraZeneca y Oxford – which has already been approved within the UK – has but to use for authorization within the EU, though it’s anticipated to take action quickly.